1. Home
  2. Browse Decisions
  3. F.Supp.2d
  4. 910 F.Supp.2d
  5. 910 F.Supp.2d 299 (2012)
 

MYLAN LABORATORIES LTD. v. U.S. FOOD & DRUG ADMIN.

Civil Action No. 12-1637 (JDB).

910 F.Supp.2d 299 (2012)

MYLAN LABORATORIES LTD.; Mylan Pharmaceuticals, Inc., Plaintiffs, v. U.S. FOOD AND DRUG ADMINISTRATION, et al., Defendants, and Ranbaxy Laboratories Limited, Intervenor-Defendant.

United States District Court, District of Columbia.

December 27, 2012.

Attorney(s) appearing for the Case

Edward Anthony Figg , Rothwell, Figg, Ernst & Manbeck, PC, Washington, DC, Eric R. Hunt , Lara E. Fitzsimmons , William A. Rakoczy , Rakoczy Molino Mazzochi Siwik LLP, Chicago, IL, Sharon Lynch Davis , Rothwell, Figg, Ernst & Manbeck, P.C., Washington, DC, for Plaintiffs.

Andrew E. Clark , U.S. Department of Justice, Washington, DC, for Intervenor-Defendant.

MEMORANDUM OPINION

JOHN D. BATES, District Judge.

On September 28, 2012, the Food and Drug Administration ("FDA") decided that Ranbaxy Laboratories Limited ("Ranbaxy") had not forfeited its eligibility for 180-day exclusivity to market generic valsartan tablets. Because of this decision, plaintiffs Mylan Laboratories Limited and Mylan Pharmaceuticals, Inc. ("Mylan") are blocked from marketing their generic valsartan tablets. Mylan brings this action...

Let's get started

Leagle.com

Welcome to the leading source of independent legal reporting
Sign on now to see your case.
Or view more than 10 million decisions and orders.

  • Updated daily.
  • Uncompromising quality.
  • Complete, Accurate, Current.

Listed below are the cases that are cited in this Featured Case. Click the citation to see the full text of the cited case. Citations are also linked in the body of the Featured Case.

Cited Cases

  • No Cases Found

Listed below are those cases in which this Featured Case is cited. Click on the case name to see the full text of the citing case.

Citing Cases